Mutational Landscape in Resected Periampullary Adenocarcinoma: Relationship With Morphology and Clinical Outcome

Research output: Contribution to journalArticle


title = "Mutational Landscape in Resected Periampullary Adenocarcinoma: Relationship With Morphology and Clinical Outcome",
abstract = "PURPOSE Periampullary adenocarcinomas encompass a heterogeneous group of tumors with dismal prognosisand limited treatment options. Emerging evidence shows that tumor morphology (ie, intestinal type [I-type] orpancreatobiliary type [PB-type]) is a more relevant prognostic factor than tumor origin. Knowledge is sparse,however, on whether key mutations differ according to morphology.MATERIALS AND METHODS Next-generation sequencing was applied to assess the mutational status of 70 genesin 102 tumors from a retrospective cohort of 175 patients with resected periampullary adenocarcinoma.Brahma-related gene 1 protein expression was examined by immunohistochemistry on tissue microarrays withprimary tumors from the original cohort.RESULTS APC mutations were significantly more common in I-type than in PB-type tumors (27.5{\%} v 0{\%};P , .001), as were ERBB3 mutations (20.8{\%} v 4.8{\%}; P = .016), whereas CDKN2A mutations were morecommon in PB-type than in I-type tumors (19.4{\%} v 2.5{\%}; P = .013). KRAS mutation was an independentfactor of poor prognosis in I-type tumors (hazard ratio, 3.73; 95{\%} CI, 1.10 to 12.67). In PB-type tumors,SMARCA4 mutation was an adverse prognostic factor in patients not receiving adjuvant chemotherapy,and there was a significant treatment interaction between expression of Brahma-related gene 1 protein, theprotein encoded by SMARCA4, and adjuvant chemotherapy (Pinteraction = .007).CONCLUSION To our knowledge, this is the first description of the mutational landscape in the full spectrum ofperiampullary adenocarcinoma that demonstrates that the distribution and prognostic and predictive significanceof commonly mutated genes differ by morphology. The results emphasize that morphology is an importantfactor to consider in the search for novel biomarkers and targeted personalized treatment of these patients. Inaddition, the findings support the concept that molecular profiling of these tumors could be of clinical benefit.",
author = "Sebastian Lundgren and {Olsson Hau}, Sofie and Jacob Elebro and Margareta Heby and Emelie Karnevi and Bj{\"o}rn Nodin and Jakob Eberhard and Karolina Holm and Johan Staaf and J{\"o}nsson, {G{\"o}ran B} and Karin Jirstr{\"o}m",
year = "2019",
month = "3",
day = "21",
doi = "10.1200/PO.18.00323 JCO",
language = "English",
volume = "3",
pages = "1--8",
journal = "JCO Precision Oncology",
issn = "2473-4284",
publisher = "American Society of Clinical Oncology",